Valneva SE
VALNHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Valneva SE focuses on Biotechnology services and products. Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. Valued at $649.5M, VALN is a small-cap name in its sector. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Market Cap
$649.5M
Beta
1.37
P/E (TTM)
—
P/E (Fwd)
5.76
EPS (TTM)
$-2.08
EPS (Fwd)
$1.19
ROE
-117.9%
ROA
-16.7%
Cash
$121.5M
Total Debt
$210.2M
Free CF
-$42.5M
52W Change
-22.8%
Annual Financials
Cash vs Debt
Where VALN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VALN finished 3.94% above its 150-day moving average ($6.85) and 3.78% below its 200-day moving average ($7.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VALN overbought or oversold?
At the September 3, 2026 close, VALN's RSI(14) was 71.2, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $121.5M in cash, though total debt stands at $210.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$42.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -117.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $361.3M to $174.7M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing VALN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.